NEXTAGE Therapeutics Ltd.

As of December 31, 2025, NEXTAGE Therapeutics Ltd. carries a market capitalization of 6.31B, placing it among publicly traded companies globally. Its enterprise value stands at 7.99B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, NEXTAGE Therapeutics Ltd. has 81.06M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, NEXTAGE Therapeutics Ltd. maintains a current ratio of 0.06, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, NEXTAGE Therapeutics Ltd.'s stock has declined approximately 51.99% over the past 52 weeks. The 50-day moving average sits at 37.91, while the 200-day moving average is 61.90.

As of December 31, 2025, NEXTAGE Therapeutics Ltd. holds 27.90M in cash and equivalents against 1.73B in total debt, resulting in a net debt position of 1.64B. Total book value stands at 1.42B, with working capital of -2.70B providing operational flexibility.

NEXTAGE Therapeutics Ltd.'s most recent stock split took place on April 12, 2020 with a 20:1 split ratio.